an mrna vaccine candidate bnt162b1 against covid-19 produced little increase in sars-cov-2 neutralizing agents in a phase 1 study.
an mrna vaccine candidate bnt162b1 against covid-19 produced little increase in sars-cov-2 neutralizing agents in a phase 1 study.